相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Change is possible: How increased patient activation is associated with favorable changes in well-being, self-management and health outcomes among people with type 2 diabetes mellitus: A prospective longitudinal study
Hannah Regeer et al.
PATIENT EDUCATION AND COUNSELING (2022)
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer et al.
KIDNEY INTERNATIONAL (2022)
Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
Ryan Pelletier et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2021)
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
David Z. I. Cherney et al.
DIABETOLOGIA (2021)
From glucose lowering agents to disease/diabetes modifying drugs: a SIMPLE approach for the treatment of type 2 diabetes
Ofri Mosenzon et al.
CARDIOVASCULAR DIABETOLOGY (2021)
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown et al.
LANCET (2021)
Characteristics and treatment patterns of patients with type 2 diabetes in Lebanon: the DISCOVER study
Sami T. Azar et al.
EASTERN MEDITERRANEAN HEALTH JOURNAL (2021)
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Jennifer M. Trujillo et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2020 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2020)
Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?
Francesco Giorgino et al.
DIABETES OBESITY & METABOLISM (2020)
Prevalence and clinical characteristics of diabetes mellitus in Lebanon: a national survey
Ibrahim Bou-Orm et al.
EASTERN MEDITERRANEAN HEALTH JOURNAL (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Hypoglycaemia assessment tool (HAT) study: subanalysis of the Lebanese cohort
Mireille Amm et al.
EASTERN MEDITERRANEAN HEALTH JOURNAL (2020)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE ALGORITHM-2020 EXECUTIVE SUMMARY
Yehuda Handelsman et al.
ENDOCRINE PRACTICE (2020)
The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study)
Neda Laiteerapong et al.
DIABETES CARE (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiorenal Disease Is the Most Common First CV Manifestation in Type 2 Diabetes and Associated with Increased Mortality: A Large Multinational Observational Study
Kare I. Birkeland et al.
DIABETES (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
Guntram Schernthaner et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Multidisciplinary collaborative care in the management of patients with uncontrolled diabetes: A systematic review and meta-analysis
Melanie Yee Lee Siaw et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Hiddo J L Heerspink et al.
Lancet Diabetes & Endocrinology (2019)
Management and control of type 2 diabetes mellitus in Lebanon: Results from the International Diabetes Management Practices Study Wave 6
Hala Ahmadieh et al.
WORLD JOURNAL OF DIABETES (2019)
Multidisciplinary coordinated care for Type 2 diabetes: A qualitative analysis of patient perspectives
Seth A. Berkowitz et al.
PRIMARY CARE DIABETES (2018)
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams et al.
EUROPEAN HEART JOURNAL (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Kare I. Birkeland et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Diet, physical activity and socio-economic disparities of obesity in Lebanese adults: findings from a national study
Marie Claire Chamieh et al.
BMC PUBLIC HEALTH (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals
Frank Lavernia et al.
POSTGRADUATE MEDICINE (2015)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
Prevalence, correlates and management of type 2 diabetes mellitus in Lebanon: Findings from a national population-based study
Christy Costanian et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward
Adeera Levin et al.
KIDNEY INTERNATIONAL (2014)
Primary care physicians' familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study
Khaled Abdel-Kader et al.
BMC NEPHROLOGY (2014)
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
Hans-Ulrich Haering et al.
DIABETES CARE (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Role of self-care in management of diabetes mellitus
Saurabh RamBihariLal Shrivastava et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2013)
Trends in overweight and obesity in Lebanon: evidence from two national cross-sectional surveys (1997 and 2009)
Lara Nasreddine et al.
BMC PUBLIC HEALTH (2012)
High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
L. J. M. Boonman-de Winter et al.
DIABETOLOGIA (2012)
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
Caroline S. Fox et al.
LANCET (2012)
Impact of the US Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
Boaz Hirshberg et al.
DIABETES CARE (2011)
Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Richard M. Bergenstal et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Faramarz Ismail-Beigi et al.
LANCET (2010)
Cardiorenal Syndrome
Claudio Ronco et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Effect of a multifactorial intervention on mortality in type 2 diabetes
Peter Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Earlier intervention in type 2 diabetes: The case for achieving early and sustained glycaemic control
CJ Bailey et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2005)
Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: Evidence for lack of physician awareness of chronic kidney disease
LA Stevens et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Mortality and causes of death in the WHO multinational study of vascular disease in diabetes
NJ Morrish et al.
DIABETOLOGIA (2001)
分享论文
